Development of a diagnostic method for pancreatic cancer using 13C glucose

Phase 1

Recruiting

• Conditions: Pancreatic cancer, benign pancreatic diseases, or other gastroenterological cancers; Pancreatic cancer

• Registration Number: JPRN-jRCTs051210205
• Lead Sponsor: Tobimatsu Kazutoshi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-03-25
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Age over 20, under 80
2. Diagnosed patients of pancreatic cancer, benigh pancreatic disease or other gastroenterological cancer
3. Patients who have given their free and written consent to participate in this clinical research.

Exclusion Criteria

1. ECOG-PS 4, or patients who have difficulty urinating or collecting urine on their own
2. Patients deemed inappropriate by the attending doctor

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evel of 13C glucose-derived metabolites present in urine after 13C glucose administration

Secondary Outcome Measures

Name	Time	Method
1. Presence of 13C glucose-derived metabolites in urine after administration of 13C glucose<br>2. 13C glucose-derived metabolites (unknown metabolites)<br>3. Metabolites containing 13C<br>4. Occurrence of disease or symptom